I am referring to HMG-CoA reductase inhibitors. Use of those drugs has been shown to improve health in people suffering from diabetes, obesity, hypertension, hyperlipidemia, atherosclerosis, cardiovascular and cerebrovascular diseases such as coronary heart diseases and stroke, fatty liver, and lipid metabolism.
This sounds amazing. HMG CoA reductase inhibitors are statins that can lower LDL and cholesterol. Various versions have been used in the past for patients and the results show that they indeed work.
A recent patent shows a “mixture” of such statins working incredibly well in the results of the inventor. The grant was approved recently on that case.
They work by inhibiting HMG-CoA reductase, an enzyme producing cholesterol.
Statins have been around since 1980. Recent studies focus on the need for such statins to have such effects on HIV patients, but they don’t appear to do so.
The recent advancements in this field look promising but we need additional studies (hopefully utilising independent funding) to investigate all those claims and results.The links to all the articles are provided below for you to look into the details. There is not much informations since this combination of statins, drug is being developed and i cannot find second sources confirming the exact experiment with the same mixture. simvastatin, atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, pitavastatin, bervastatin, cerivastatin, crilvastatin, dalvastatin, mevasatin or tenivastatin; preferably simvastatin, atorvastatin, fluvastatin, rosuvastatin; the most preferably simvastatin. This mixture in this case is supposed to be even more efficient when used locally even in bone.
Upregulation of Endothelial Nitric Oxide Synthase by HMG CoA Reductase Inhibitors, HMG-CoA reductase inhibitors, Use of a statin compound as topical drug for treating obesity, diabetes, hypertension and hyperlipemia, Low density lipoprotein cholesterol response after statin initiation among persons living with HIV, Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.